E Mannucci, M Monami, C Lamanna, F Gori, N … - Nutrition, Metabolism and Cardiovascular Diseases, 2009 - Elsevier Five studies (17,267 and 15,362 patients in the intensive and conventional
therapy groups, respectively) were included. Intensive treatment, which reduced
mean HbA1c by 0.9% on average, was associated with a significant reduction ... Cited by 6 - Related articles - All 4 versions
P Ambery, AR Cobitz - Diabetologia, 2009 - Springer To the Editor: GlaxoSmithKline regrets the recommendation [1] of the recent
consensus statement from the American Diabetes Association and the European
Association for the Study of Diabetes against the use of rosiglitazone for ... Related articles - All 2 versions
E Erdmann, B Charbonnel, R Wilcox - Current Cardiology Reviews, 2009 - ingentaconnect.com Abstract: Background: Several recent meta-analyses of adverse event data from
randomized controlled trials with rosiglitazone reveal a possible association
between this thiazolidinedione and an increased risk of ischemic myocardial ... Related articles
- ►glucagon.com [PDF] K Ban, S Hui, DJ Drucker, M Husain - Journal of the American Society of Hypertension, 2009 - Elsevier Cardiovascular disease is the predominant cause of death in diabetic patients,
and yet the cardiovascular benefits of traditional drug treatments for
hyperglycemia have been elusive. Two new classes of diabetic drugs ... Related articles - All 11 versions
SE Kahn, WT Cefalu - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc It is noteworthy that the last few years have seen the release of a wealth of
new information regarding glycemia and diabetes complications, with much
attention focused on glucose control and macrovascular disease. Although ... Related articles - All 3 versions
EZ Fisman, A Tenenbaum - Cardiovascular Diabetology, 2009 - cardiab.com Classical non-insulin antihyperglycemic drugs currently approved for the
treatment of type 2 diabetes mellitus (T2DM) comprise five groups: biguanides,
sulfonylureas, meglitinides, glitazones and alpha-glucosidase inhibitors. ... Related articles - Cached - All 8 versions
- ►171.66.125.180 R Nahas, M Moher - Canadian Family Physician, 2009 - cfp.ca More than one-third of Canadians are using complementary and alternative
medicine (CAM) therapies, 6 often without consulting or even informing their
FPs. It is important for FPs to ask patients about their CAM use and ... Related articles - All 8 versions
AH Barnett - Diabetes, Obesity and Metabolism, 2009 - interscience.wiley.com Vildagliptin is a potent and selective oral dipeptidyl peptidase-4 inhibitor
that improves glycaemic control in patients with type 2 diabetes mellitus (T2DM)
by increasing both α- and β-cell responsiveness to glucose. The efficacy, ... Related articles - All 3 versions
- ►eje.org B Hemmingsen, SS Lund, J Wetterslev, A … - European Journal of Endocrinology, 2009 - EFES This article is a narrative review of the current evidence of the effects on
cardiovascular disease (CVD) of oral hypoglycaemic agents that increase insulin
sensitivity in patients with type 2 diabetes (T2D). In overweight T2D ... Related articles - All 9 versions
BAF INSULINRESISTENS - Ugeskr Læger, 2009 - ugeskriftet.dk Forekomsten af type 2-diabetes (T2D) stiger verden over [1]. Insulinresistens i
perifere væv og utilstræk- keligt kompenseret insulinsekretion er væsentlige
elementer i T2D-patogenesen. Den nedsatte insu- linsekretion forårsages af ... Related articles - View as HTML
